Evidence map›Paper›PMID 27852236›Full record

Trial reportBMC nephrology2016

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.

Matthew A Roberts, Louis Huang, Darren Lee, Robert MacGinley, Stefanie M A Troster, Annette B Kent, Sukhvinder S Bansal, Iain C Macdougall, Lawrence P McMahon

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Intravenous iron therapy for non-anaemic, iron-deficient adults.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. The regulation of FGF23 under physiological and pathophysiological conditions.Pflugers Archiv : European journal of physiology · 2022
    Review
  6. The Role of DMP1 in CKD-MBD.Current osteoporosis reports · 2021
    Review
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Bone and heart health in chronic kidney disease: role of dentin matrix protein 1.Current opinion in nephrology and hypertension · 2019
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Matthew A RobertsEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
Louis HuangEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
Darren LeeEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
Robert MacGinleyEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
Stefanie M A TrosterDepartment of Renal Medicine, Eastern Health, Box Hill, VIC, Australia.
Annette B KentEastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
Sukhvinder S BansalInstitute of Pharmaceutical Science, King's College, London, UK.
Iain C MacdougallDepartment of Renal Medicine, King's College Hospital, London, UK.
Lawrence P McMahonEastern Health Clinical School, Monash University, Box Hill, VIC, Australia. Lawrence.McMahon@easternhealth.org.au.
Monash University · AUEastern Health · AUKing's College Hospital · GBKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron used.

methodsPrevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured. Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment and time evaluated between-group effects.

resultsForty-two participants completed the study. In those randomized to FCM (n = 22), median (interquartile range) values pre-infusion and Day 2, respectively, were 843 pg/mL (313-1922) and 576 pg/mL (356-1296, p = 0.05) for iFGF23, 704RU/mL (475-1204) and 813RU/mL (267-1156, p = 0.04) for cFGF23, and 1.53 mmol/L (1.14-1.71) and 1.37 (1.05-1.67, p = 0.03) for phosphate. These parameters did not change following IS. Both serum ferritin (p < 0.001) and hepcidin (p < 0.001) increased in both groups, and the increase in hepcidin was greater in the FCM group (p = 0.03 for between-group difference).

conclusionsContrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This suggests a differential effect of intravenous iron treatment according to both formulation and renal function.

trial registrationAustralian and New Zealand Clinical Trials Register ACTRN12614000548639 . Registered 22 May 2014 (retrospectively registered).

Indexed as

Administration, IntravenousAgedFemaleFerric CompoundsFerric Oxide, SaccharatedFibroblast Growth Factor-23Fibroblast Growth FactorsGlucaric AcidHematinicsHumansMaleMaltoseMiddle AgedRenal DialysisRenal Insufficiency, Chronicferric carboxymaltoseFerric CompoundsFerric Oxide, SaccharatedFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsGlucaric AcidHematinicsMaltoseFibroblast growth factor-23HaemodialysisHepcidinIron infusionRandomized controlled trial

Identifiers

PMID27852236
PMCPMC5112660
OpenAlexW2556729497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.